article thumbnail

Drugging RNA with pills: small molecules for a big frontier

Bio Pharma Dive

A handful of startups have formed in recent years with plans to target RNA with small molecules. Many have caught the attention of big drugmakers

RNA 291
article thumbnail

Next-generation RNA technologies: making longer-lasting drugs with a broader reach

Bio Pharma Dive

At least 10 biotechnology startups are trying to use RNA molecules in new ways to make medicines. Here’s a look at where they stand

RNA 329
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

China-based biotech licenses Sanofi's RNA drug technology

Bio Pharma Dive

The Lilly-backed Rona Therapeutics gains rights to a platform for small interfering RNA, along with a slate of preclinical candidates aimed at targets in the liver and other tissues

RNA 246
article thumbnail

Amgen partners with Arrakis to develop drugs aimed at RNA

Bio Pharma Dive

Arrakis, a specialist in designing oral drugs that target RNA, will receive $75 million under the deal, which could be worth "several billion dollars" more

RNA 257
article thumbnail

2nd Next Generation RNA Therapeutics Summit

Pharma Phorum

Bringing Next Generation RNA Therapies to Patients Faster. The post 2nd Next Generation RNA Therapeutics Summit appeared first on. Events Oncology Immunotherapies rna RNA conference tRNAs vaccine

RNA 52
article thumbnail

Ascidian starts up with $50M and a twist on RNA editing

Bio Pharma Dive

The startup, run by Translate Bio cofounder Romesh Subramanian, believes its RNA “exon editing” approach could have long-lasting effects without the risks that come with editing DNA

RNA 257
article thumbnail

Moderna founder unveils new drug company focused on a different kind of RNA

Bio Pharma Dive

The biotech is researching how to make medicines from transfer RNA molecules Encouraged by Moderna's success, Flagship Pioneering has been busy creating startups like Alltrna, which launched Tuesday.

RNA 359
article thumbnail

Merck makes circular RNA play with $3.5bn Orna alliance

Pharma Phorum

Merck & Co has ramped up its involvement in the RNA category, partnering with US biotech Orna Therapeutics in a deal valued at up to $3.5 Now, Merck has made its own play, partnering with Orna on its proprietary ‘oRNA’ technology, which stands for circular RNA.

RNA 98
article thumbnail

Beam-linked startup launches with an eye on the next generation of RNA drugs

Bio Pharma Dive

“We see a huge opportunity in the setting of RNA-based therapies to overcome some of the shortcomings that have been there with the first generation of RNA companies,” said former Alnylam CEO and Orbital Therapeutics co-founder John Maraganore

RNA 229
article thumbnail

The Decade of RNA Delivery – Beyond the Liver

BioSpace

The Decade of RNA Delivery – Beyond the Liver 3/8/2023

RNA 100
article thumbnail

AstraZeneca gives up on Ionis’ RNA drug for heart disease

Bio Pharma Dive

The British drugmaker decided the medicine, which works similarly to Novartis’s Leqvio, wasn’t potent enough to justify further testing

RNA 308
article thumbnail

J&J to explore RNA reprogramming with Remix research deal

Bio Pharma Dive

The agreement with the Cambridge-based startup is the latest to reflect growing large pharma company interest in targeting RNA with small molecules

RNA 192
article thumbnail

As Arrowhead falters, lungs remain a tough target for RNA drugs

Bio Pharma Dive

The biotech's decision to pause testing of a cystic fibrosis drug is the latest reminder of the difficulty of delivering RNA medicines into the lungs

RNA 297
article thumbnail

Beyond Covid-19: the disruptive potential of RNA-based therapeutics

Pharmaceutical Technology

Further, the acceptance of new mRNA vaccines has rejuvenated activity within previously established categories of RNA therapeutics including lifesaving antisense technologies. These include antisense oligonucleotides (ASO), RNA interference (RNAi), and RNA aptamers.

RNA 147
article thumbnail

14th Annual RNA Therapeutics Conference

Pharma Phorum

14th Annual RNA Therapeutics. Investigating the next generation of genetic medicine through RNA based therapies. This is reflected with the value of the global antisense & RNA therapeutics market expected to reach USD 1.81 Who should attend: Directors of novel RNA therapies.

RNA 52
article thumbnail

Venture capital pours more money into RNA medicines with the launch of Replicate

Bio Pharma Dive

The company, which focuses on self-replicating RNA, comes equipped with $40 million from Apple Tree Partners and a stamp of approval from the former research head at Biogen

RNA 271
article thumbnail

Moderna founder's next big play in RNA raises $440 million

Bio Pharma Dive

Just a few months out of stealth mode, Laronde and its "endless RNA" technology have caught the attention of well-known investors like Fidelity, T. Rowe Price Associates and Invus

RNA 349
article thumbnail

RNA Therapeutics 2022

Pharma Phorum

SMi Group’s 13th Annual Conference: RNA Therapeutics 2022. Bolstering the latest advances and opportunities in RNA-based medicine. Delve into the latest innovations in novel RNA delivery and target specificity. Head of RNA Biology.

RNA 52
article thumbnail

Next Generation RNA Therapeutics Summit

Pharma Phorum

Are you looking to solve challenges with current RNA therapeutics, such as the degradation of RNA by RNAses, the difficulty of RNA crossing the cell membrane by diffusion and the immunogenicity elicited by exogenous RNA? Next generation RNA therapeutics can help!

RNA 52
article thumbnail

Eli Lilly Expands RNA Editing Collaboration with ProQR Therapeutics

BioSpace

Eli Lilly and ProQR Therapeutics expand their RNA-editing collaboration

RNA 100
article thumbnail

Gatehouse Bio and AstraZeneca to develop RNA therapeutics for heart failure

Pharmaceutical Technology

US-based biotech company Gatehouse Bio is extending its collaboration with AstraZeneca for developing RNA therapeutics to treat heart failure with preserved ejection fraction (HFpEF). Gatehouse Bio is engaged in developing small RNA-based therapeutics using AI technology.

RNA 246
article thumbnail

BioTuring enters collaboration to enable detailed single-cell RNA research

Pharma Phorum

The collaboration aims to “close the gap between single-cell RNA sequencing wet-lab services and single-cell data analysis solutions,” which will allow scientists to study the finest details that can be hard to access. News R&D pharma rna rna therapeutics Single Cell Analysis

RNA 72
article thumbnail

Roche adds to RNA drug deal streak with Ribometrix partnership

Bio Pharma Dive

The companies' pact is the latest addition to a growing list of deals involving startups developing chemical drugs to target RNA molecules

RNA 166
article thumbnail

Eli Lilly Pursues RNA Editing in New Partnership with ProQR

XTalks

billion deal will see the companies use ProQR’s proprietary Axiomer RNA editing platform technology to advance editing oligonucleotide-based therapeutics toward clinical development and commercialization.

RNA 101
article thumbnail

Lilly joins RNA editing race with ProQR deal

Bio Pharma Dive

An agreement with the Dutch biotech, which could be worth as much as $1.3 billion, expands Lilly's work in genetic medicine research

RNA 257
article thumbnail

Hallmark cancer gene regulates RNA ‘dark matter’

Scienmag

A key genetic mutation that occurs early on in cancer alters RNA “dark matter” and causes the release of previously unknown RNA biomarkers for cancer early detection, a new study by UC Santa Cruz researchers published in the journal Cell Reports shows. Cancer cancer dark gene Hallmark matter regulates RNA

RNA 64
article thumbnail

Merck pays startup Orna $150M as ‘circular RNA’ attracts industry interest

Bio Pharma Dive

The pharmaceutical company has formed an alliance with Orna and invested $100 million in its Series B round, hoping the young biotech’s approach could lead to multiple new vaccines and drugs

RNA 283
article thumbnail

Lilly pays $75M to widen RNA editing deal with ProQR

Bio Pharma Dive

The expanded deal triples the amount of money the biotech could eventually receive from Lilly and adds several more neurological disease drug targets

RNA 140
article thumbnail

Messenger RNA technology shows promise for developing infectious disease therapeutics

Scienmag

Army scientists and industry partners were among the first to demonstrate that messenger RNA (mRNA)—the technology recently used in COVID-19 vaccines and others—could also be used to develop treatments for infectious diseases.

RNA 81
article thumbnail

Double-stranded RNA induces bone loss during gum disease

Scienmag

They found that double stranded RNA molecules can activate the immune system response that leads to deterioration of bone. Medicine & Health bone Disease Doublestranded gum induces loss RNA

RNA 86
article thumbnail

Biogen taps Envisagenics’ AI to speed up RNA splicing R&D

Pharma Phorum

Biogen has made a further push into RNA-based drug discovery via a collaboration with Envisagenics, which applies artificial intelligence RNA sequencing data to discover new drug targets and therapeutics. Cambridge, Massachusetts-based Envisagenics focuses on using AI to analyse errors in RNA splicing, a process in which a precursor form of messenger RNA (mRNA) – which is used as a template for protein synthesis in cells – is transformed into a mature form.

RNA 60
article thumbnail

Lilly buys into MiNA’s protein-boosting RNA tech in $1.25bn deal

Pharma Phorum

UK biotech MiNA Therapeutics has signed up another big pharma partner for its small activating RNA (saRNA) platform, which upregulates the activity of proteins, with Eli Lilly the latest to get in on the action. . News R&D Eli Lilly MiNA Therapeutics partnering rna RNA-based drugs

RNA 76
article thumbnail

2nd RNA Editing Summit 2020

Pharma Phorum

The only industry-led meeting showcasing the recent development of RNA editing mechanisms and dedicated to realizing the research and therapeutics opportunity of RNA editing as quickly as possible. The post 2nd RNA Editing Summit 2020 appeared first on.

RNA 52
article thumbnail

How RNA-Based Pesticides Can Improve Pest Control

XTalks

Perhaps popularized by the COVID-19 vaccines, RNA-based technologies now have the potential to become the next best pesticide to combat crop pests, like insects and fungal pathogens. What are RNA-Based Pesticides? Advantages of RNA-Based Pesticides.

RNA 92
article thumbnail

UTSW study: RNA exosome key for B cell development

Scienmag

New research from UT Southwestern suggests that RNA exosomes – the cellular machines that degrade old molecules of RNA – play a key role in the development of B cells, which are critical to the immune system’s ability to protect against infection.

RNA 70
article thumbnail

RNA Therapeutics Experience Renaissance Amidst Global Pandemic

BioSpace

RNA caught the public’s imagination in the form of mRNA vaccines against COVID-19, but RNA can be used in other ways, too, to make therapeutic proteins

RNA 98
article thumbnail

Benchling launches purpose-built tools to accelerate RNA R&D

BioPharma Reporter

Technology firm, Benchling, has developed what it calls the biopharma industryâs first set of full capabilities for designing, modelling, and studying both natural and chemically modified RNA in a single platform.

RNA 119
article thumbnail

Switch Therapeutics launches with $52M to capitalize on RNA medicine ‘era’

Bio Pharma Dive

The company’s name comes from its goal of developing drugs that only “switch” on in target cells, potentially enabling more precise therapies

RNA 130
article thumbnail

???????Research sheds light on mysterious messenger RNA modifications

Scienmag

A team led by scientists at the University of Birmingham has come a step closer to uncovering the purpose of a distinctive set of modifications found at the beginning of messenger RNA which have long remained a fundamental mystery in molecular biology.

RNA 80
article thumbnail

CAMP4’s funding influx paves the way for tapping regulatory RNA to treat urea cycle disorders

Pharmaceutical Technology

Last week, CAMP4 Therapeutics announced the close of a $100 million Series B round , which will be used to advance their regulatory RNA (regRNA)-focused programs. In order to find the specific RNA sequences for a genetic disease, the biotech is using an AI- and machine learning-based approach.

RNA 245
article thumbnail

Lucerna is Illuminating the Mysteries of RNA to Solve Disease

BioSpace

The company aims to make RNA molecules visible and druggable – opening the door to study RNA-based diseases

RNA 105
article thumbnail

Single cell RNA sequencing uncovers new mechanisms of heart disease

Scienmag

Biology cell Disease heart mechanisms RNA sequencing single uncoversHypertrophic cardiomyopathy is a heart disease that leads to a stressed, swollen heart muscle. Due to a poor understanding of underlying mechanisms, effective clinical treatments are not available.

RNA 82
article thumbnail

GSK dives into NASH, RNA interference with Arrowhead deal

Bio Pharma Dive

GSK has secured rights to a genetic medicine in early-stage human testing for NASH, a disease thought to affect millions of people and which has proven to be a tough target for drugmakers

RNA 180